Vertex scores FDA approval for new cystic fibrosis drug

Vertex Pharmaceuticals said Monday that the FDA has approved its third drug for cystic fibrosis, lifting shares of the Boston-based company. Vertex (Nasdaq: VRTX) said the drug — a combination of Kalydeco, which was approved in 2012, and a new medicine called tezacaftor — will be sold under the brand name Symdeko. It will begin shipping to pharmacies in the U.S. this week, and will have a list price of $292,000 per year, the compa ny said. "This approval is an important milestone in our journey…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news